Zura Bio Q2 net loss widens as R&D expenses rise

Zura Bio

11/08/2026 12:39

Overview
US biotech firm's Q2 net loss widened yr/yr as R&D expenses rose
Company completed enrollment in two Phase 2 tibulizumab studies, both exceeding initial targets
Cash and cash equivalents of $205.1 mln expected to fund operations through at least end of 2028

Outlook
Topline data from TibuSHIELD Phase 2 study expected in Q4 2026
Topline data from TibuSURE Phase 2 study expected in H1 2027
Company expects to initiate Phase 2 study in PMR by year-end 2026
Company expects cash to fund operations through at least end of 2028

Result Drivers
R&D SPENDING - Higher research and development expenses driven by advancement of Phase 2 tibulizumab clinical programs
LOWER PROFESSIONAL FEES - General and administrative expenses decreased due to lower expense in professional fees

Company press release: ID:nBw84HMHna

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$26.30 mln
 
Q2 loss from Operations
 
-$29.32 mln
 
Q2 Operating Expenses
 
$29.32 mln
 
Q2 Pretax Loss
 
$26.39 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Zura Bio Ltd is $15.50, about 175.3% above its August 10 closing price of $5.63

Reuters Recommended Reads
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 11 - Shattuck Labs Q2 net loss widens as R&D spending rises
Aug 10 - MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)